Kikuchi, Jun

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Rheumatology) (Shinanomachi)

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)
Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Connective tissue disease and allergy

Page Top ▲

Research Keywords 【 Display / hide 】

  • Systemic lupus erythematosus

  • Rheumatoid arthritis

Page Top ▲
 

Papers 【 Display / hide 】

  • 大量ステロイドとトシリズマブ治療経過中に巨細胞性動脈炎による重症脳梗塞を発症した一例

    鈴木 浩司, 秋山 光浩, 花岡 洋成, 近藤 泰, 齋藤 俊太郎, 菊池 潤, 金子 祐子

    関東リウマチ (関東リウマチ研究会)  55   7 - 11 2023.05

    ISSN  0911-4807

    　View Summary

    症例は77歳女性で、発熱、両肩関節の疼痛・挙上困難、顎跛行を主訴とした。血液検査、画像所見(PET-CT、頭部造影MRI)、右側頭動脈生検より、巨細胞性動脈炎と診断した。大量ステロイドとトシリズマブを開始したが、重症脳梗塞を発症し、ステロイドパルスとシクロフォスファミドによる再寛解導入療法を行い、病勢をコントロールできた。脳梗塞に対してはアスピリンとクロピドグレルを開始した。本症例は高齢、高血圧、顎跛行、炎症マーカー低値で、PET-CTで内頸動脈への集積亢進を認めるなど脳梗塞のリスクが高かった。

  • Deep remission within 12 months prevents renal flare and damage accrual in lupus nephritis.

    Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Takeuchi T, Kaneko Y

    Clinical and experimental rheumatology  2023.01

    ISSN  0392-856X

  • Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients.

    Saito S, Suzuki K, Yoshimoto K, Kondo Y, Kikuchi J, Hanaoka H, Kaneko Y, Takeuchi T

    Clinical and experimental rheumatology  2022.12

    ISSN  0392-856X

  • Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment.

    Hiroshi Takei, Satoshi Takanashi, Kotaro Otomo, Hironari Hanaoka, Jun Kikuchi, Kunihiro Yamaoka, Keiko Yoshimoto, Takayuki Abe, Tsutomu Takeuchi, Yuko Kaneko

    Modern rheumatology  2022.12

    ISSN  1439-7595

    　View Summary

    OBJECTIVE: To investigate the efficacy and safety of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA). METHODS: Patients with active RA, despite conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), were recruited. HCQ was administered for 24 weeks, in addition to prior treatment. The primary endpoint was the proportion of American College of Rheumatology (ACR) 20 achievement at week 24, compared to that of a propensity score matched historical control group. RESULTS: Sixty patients were enrolled and administered HCQ. We also identified 276 patients as candidates for the historical control group. Propensity score matching yielded 46 patients in each group. The proportion of ACR20 achievements at week 24 was significantly higher in the HCQ group than that in the control group (54.4% vs. 28.3%, P = 0.007). The proportion of ACR50 and ACR70 achievement at week 24 were also higher in the HCQ group than those in the control group (ACR50, 30.4% vs. 4.3%, P = 0.006; ACR70, 17.4% vs. 0%, P = 0.005). Neither hydroxychloroquine retinopathy nor any new safety signal was observed during the study. CONCLUSION: The addition of HCQ to csDMARDs was effective, with no new safety signal in patients with RA.

  • Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study

    Connelly K., Kandane-Rathnayake R., Hoi A., Louthrenoo W., Hamijoyo L., Cho J., Lateef A., Fen Luo S., Wu Y.J.J., Li Z., Navarra S., Zamora L., Sockalingam S., Hao Y., Zhang Z., Katsumata Y., Harigai M., Oon S., Chan M., Chen Y.H., Bae S.C., O'Neill S., Goldblatt F., Kikuchi J., Takeuchi T., Ling Ng K.P., Tugnet N., Basnayake B.M.D.B., Ohkubo N., Tanaka Y., Sing Lau C., Nikpour M., Golder V., Morand E.F.

    The Lancet Rheumatology (The Lancet Rheumatology)  4 ( 12 ) e831 - e841 2022.12

    　View Summary

    Background: The selection and categorisation of laboratory tests in disease activity measures used within systemic lupus erythematosus (SLE) trial endpoints lack strong evidence. We aimed to determine whether longitudinal improvements in routinely measured laboratory tests are associated with measures of clinical improvement in patients with baseline active SLE. Methods: We included patients from a multicentre longitudinal cohort (recruited between May 1, 2013, and Dec 31, 2019) with active SLE (SLEDAI-2K ≥6) coinciding with an abnormality in at least one of 13 routine laboratory tests, at a visit designated as baseline. At 12 months, we analysed associations between thresholds of improvement in individual laboratory test results, measured as continuous variables, and five clinical outcomes using logistic regression. Primary outcomes were damage accrual and lupus low disease activity state (LLDAS), and secondary outcomes were modified SLE responder index (mSRI), physician global assessment (PGA) improvement of at least 0·3, and flare. Findings: We included 1525 patients (1415 [93%] women and 110 [7%] men, 1328 [87%] Asian ethnicity) in separate subsets for each laboratory test. The strongest associations with LLDAS and damage protection were seen with improvements in proteinuria (complete response: adjusted odds ratio [OR] 62·48, 95% CI 18·79–208·31 for LLDAS, OR 0·22, 95% CI 0·10–0·49 for damage accrual), albumin (complete response: adjusted OR 6·46, 95% CI 2·20–18·98 for LLDAS, OR 0·42, 95% CI 0·20–1·22 for damage accrual), haemoglobin (complete response: adjusted OR 1·97, 95% CI 1·09–3·53 for LLDAS, OR 0·33, 95% CI 0·15–0·71 for damage accrual), erythrocyte sedimentation rate (complete response: adjusted OR 1·71, 95% CI 1·10–2·67 for LLDAS, OR 0·53, 95% CI 0·30–0·94 for damage accrual), and platelets (complete response: adjusted OR 4·82, 95% CI 1·54–15·07 for LLDAS, OR 0·49, 95% CI 0·20–1·19 for damage accrual). Improvement in serological tests were mainly associated with PGA and mSRI. White cell and lymphocyte count improvements were least predictive. Interpretation: Improvements in several routine laboratory tests correspond with clinical outcomes in SLE over 12 months. Tests with the strongest associations were discrepant with laboratory tests included in current trial endpoints, and associations were observed across a range of improvement thresholds including incomplete resolution. These findings suggest the need to revise the use of laboratory test results in SLE trial endpoints. Funding: Abbvie.

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 皮膚エリテマトーデスの精査中に中毒性表皮壊死症様皮疹をきたし全身性エリテマトーデスの診断に至った症例

    鈴木 悠史, 鈴木 浩司, 秋山 光浩, 近藤 泰, 齋藤 俊太郎, 菊池 潤, 花岡 洋成, 金子 祐子

    日本リウマチ学会関東支部学術集会プログラム・抄録集 (日本リウマチ学会-関東支部)  33回   62 - 62 2023.12

  • 全身性エリテマトーデス患者におけるSARS-CoV-2 mRNAワクチン投与後の再燃は投与前の疾患活動性と関連する

    菊池 潤, 近藤 泰, 小島 修一郎, 葛西 志保, 堺 優真, 竹下 勝, 平本 和音, 齋藤 俊太郎, 福井 裕之, 花岡 洋成, 金子 祐子

    日本臨床免疫学会総会プログラム・抄録集 ((一社)日本臨床免疫学会)  51回   122 - 122 2023.10

  • 入院しステロイド療法を行ったリウマチ膠原病患者のサルコペニアの進行と関連する因子の探索

    花岡 洋成, 菊池 潤, 平本 和音, 秋山 光浩, 齋藤 俊太郎, 近藤 泰, 金子 祐子

    日本臨床免疫学会総会プログラム・抄録集 ((一社)日本臨床免疫学会)  51回   118 - 118 2023.10

  • 高齢発症SLE・その他　全身性エリテマトーデス患者におけるSARS-CoV-2 mRNAワクチン投与後の再燃は投与前の疾患活動性と関連する

    菊池 潤, 近藤 泰, 竹下 勝, 平本 和音, 齋藤 俊太郎, 福井 裕之, 花岡 洋成, 鈴木 勝也, 金子 祐子

    日本リウマチ学会総会・学術集会プログラム・抄録集 ((一社)日本リウマチ学会)  67回   556 - 556 2023.03

  • 関節リウマチ患者におけるSARS-CoV-2ワクチン接種後の疾患増悪に関する検討

    小島 修一郎, 近藤 泰, 堺 優真, 葛西 志保, 竹下 勝, 菊池 潤, 花岡 洋成, 鈴木 勝也, 金子 祐子

    日本リウマチ学会総会・学術集会プログラム・抄録集 ((一社)日本リウマチ学会)  67回   909 - 909 2023.03

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Investigation of novel biomarkers by multi-omics analysis of systemic lupus erythematosus

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, KIKUCHI Jun, Grant-in-Aid for Early-Career Scientists , Principal investigator

    　View Summary

    Initially, we reported that achieving a lupus low disease activity state within 12 months after starting induction therapy in active systemic lupus erythematosus (SLE) patients was associated with clinical outcomes. We then identified changes in peripheral blood immune cells following initiation of induction therapy in active SLE. In particular, we showed that the type of peripheral blood immune cells that fluctuate differed depending on the drug predominantly used as induction therapy. Furthermore, we found that fluctuations in peripheral blood plasmablasts were associated with treatment prognosis. Focusing on lupus nephritis, the analysis of urinary proteins showed that various pathways were associated with the pathogenesis associated with active and interstitial lesions in renal biopsy tissue findings.

  • Optimization of the treatment of systemic lupus erythematosus by immunological classifications

    2015.04
    -
    2018.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Principal investigator

Page Top ▲

Awards 【 Display / hide 】

  • 優秀ポスター賞

    2012.09, 日本臨床免疫学会, IL-6阻害剤とTNF阻害剤はRA患者末梢血中のCD4+CD45RO+CCR6+CD161+細胞に異なった影響を及ぼす

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, INTERNAL MEDICINE (RHEUMATOLOGY)

    2024

  • CASE STUDIES OF INTERNAL MEDICINE

    2023

  • CASE STUDIES OF INTERNAL MEDICINE

    2022

  • CASE STUDIES OF INTERNAL MEDICINE

    2021

  • CASE STUDIES OF INTERNAL MEDICINE

    2020

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本内科学会

    　

  • 日本リウマチ学会

    　

  • 日本臨床免疫学会

    　
Page Top ▲